Researchers have devised a new, promising plan of attack against deadly childhood brain cancers called diffuse midline gliomas (DMG). Scientists have shown that combining two drugs killed DMG patient cells grown in the laboratory and in animal models. The drugs countered the effects of a genetic mutation that causes the diseases. Their studies also uncovered an unrecognized vulnerability in the cancer cells that scientists may be able to exploit.